S. Steinbild

发表

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Martin Büchert, Ulrike Fasol, Oliver Boix, 2012, Clinical Cancer Research.

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

R. Kaiser, C. Unger, D. Trommeshauser, 2012, Current oncology.

Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project

M. Neurath, W. Hohenberger, T. Horbach, 2014, Oncology.

Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin

J. Drevs, C. Unger, F. Kratz, 2007, Clinical Cancer Research.

Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research-EWIV (CESAR).

D. Strumberg, M. Scheulen, C. Dittrich, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

B. Schwartz, E. Brendel, K. Mross, 2005 .

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

R. Kaiser, D. Trommeshauser, G. Munzert, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors.

R. Kaiser, D. Trommeshauser, G. Munzert, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

D. Strumberg, M. Scheulen, L. Edler, 2007, British Journal of Cancer.

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

C. Unger, M. Radtke, E. Brendel, 2007, European journal of cancer.

401 POSTER Pharmacokinetic characterization of BI 2536 - a novel Plk1 inhibitor - in advanced cancer patients

R. Kaiser, D. Trommeshauser, G. Munzert, 2006 .

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

D. Strumberg, M. Scheulen, P. Rajagopalan, 2008, British Journal of Cancer.

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

B. Schwartz, E. Brendel, D. Voliotis, 2003, International journal of clinical pharmacology and therapeutics.

Phase II Study with 3rd- or 4th-Line Bendamustine (Flat Dose) Therapy in Patients with Metastatic Breast Cancer

C. Unger, K. Mross, A. Frost, 2009, Oncology Research and Treatment.

Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study

Jürgen Hennig, Ralph Strecker, J. Hennig, 2007, Oncology Research and Treatment.

Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors

M. Büchert, C. Unger, D. Voliotis, 2007 .

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

C. Unger, D. Trommeshauser, G. Munzert, 2012, Current oncology.